The CSL Limited (ASX: CSL) share price continued its strong run on Thursday and charged higher again.
The biotherapeutics company’s latest gain means its shares have just hit an all-time high of $291.46.
Why did the CSL share price hit an all-time high?
The catalyst for yesterday’s solid gain was the de-escalation of US-Iran tensions and the release of a positive broker note out of Credit Suisse.
In respect to the latter, the broker retained its outperform rating and $305.00 price target on the company’s shares.
According to the note, the broker’s data shows that immunoglobulins demand remains strong and it feels CSL is well-positioned to benefit greatly from the high prices and tight market.
What else is driving its share price higher?
Investors have been fighting to buy CSL’s shares following a very strong performance in FY 2019.
During the 12 months CSL grew its revenue by 11% to US$8,539 million and net profit after tax at a quicker rate of 17% to US$1,919 million. Key drivers of this were strong demand for its immunoglobulins and albumin products.
Sales of immunoglobulins grew at an above-market rate of 16% to US$3,543 million in FY 2019. This was thanks to a range of factors including increased usage for chronic therapies, growing awareness and diagnosis, and the expanding usage for secondary immunodeficiency.
This ultimately led to the core CSL Behring business delivering an 11% increase in total revenue to US$7,343 million.
Supporting its growth was the Seqirus influenza vaccine business. Thanks to strong demand for its seasonal influenza vaccines, it posted a 12% increase in total revenue to US$1,196 million.
What about the future?
The good news is that brokers like Credit Suisse appear confident that there will be more of the same in FY 2020 thanks to favourable market conditions.
And with its R&D pipeline filled with promising products, the future looks bright for this biotherapeutics giant.
The post Why the CSL share price just raced to an all-time high appeared first on Motley Fool Australia.
Looking for the next CSL? Then my money would be on these top stocks providing market beating returns in 2020.
Our Motley Fool experts have just released a fantastic report, detailing 5 dirt cheap shares that you can buy in 2020.
One stock is an Australian internet darling with a rock solid reputation and an exciting new business line that promises years (or even decades) of growth… while trading at an ultra-low price…
Another is a diversified conglomerate trading near a 52-week low all while offering a 2.7% fully franked yield...
Plus 3 more cheap bets that could position you to profit over the next 12 months!
See for yourself now. Simply click the link below to scoop up your FREE copy and discover all 5 shares. But you will want to hurry – this free report is available for a brief time only.
- Man bets $221,666 on one ASX stock
- Top analysts name their top 3 ASX blue chip shares for 2019
- 3 quality dividend shares to boost your income
- NEW: Free report names top 3 ASX dividend shares to buy for 2019
- 5 Stocks for Potentially Building Wealth After 50
James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
The Motley Fool's purpose is to help the world invest, better. Click here now for your free subscription to Take Stock, The Motley Fool's free investing newsletter. Packed with stock ideas and investing advice, it is essential reading for anyone looking to build and grow their wealth in the years ahead. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson. 2020